Humacyte Files FDA Application to Add Dialysis Access as Second ATEV Use
Humacyte has submitted a supplemental Biologics License Application to the FDA, aiming to clear its bioengineered ATEV vessel for arteriovenous access in hemodialysis patients. It would be the second approved indication for the product, after Symvess won clearance for vascular trauma in December 2024.
- Original source: finance.yahoo.com.
- The source published it on Nov 19, 2026 at 5:01 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Humacyte, Inc. (Nasdaq: HUMA) said it submitted the sBLA to the U.S. Food and Drug Administration for its acellular tissue engineered vessel, or ATEV, seeking approval in arteriovenous access for hemodialysis. The filing targets patients with end-stage kidney disease who face an increased risk of AV fistula maturation failure. If cleared, dialysis access would become the ATEV's second approved indication.
The Durham, North Carolina-based company already has one approval in hand: the FDA greenlit the ATEV under the brand name Symvess in December 2024 for extremity vascular trauma. Humacyte describes itself as a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale.
The application leans on three Phase 3 studies in hemodialysis access. In the recently reported V012 Phase 3 trial, women implanted with the ATEV reached functional access more than three months sooner than women who received an AV fistula, the current standard of care, and spent significantly more time free of dialysis catheters over the first year. Women have historically seen poorer AV fistula outcomes, including higher maturation failure rates, longer waits for functional access and heavier reliance on infection-prone catheters.
CEO and co-founder Laura Niklason framed the filing around those patients. "For too long, patients on dialysis, and women in particular, have had to settle for access options that often do not work well for them," she said. "We are excited about the potential of the ATEV to provide a new potential vascular access option for hemodialysis patients in need."
Humacyte says the ATEV would be the first new option for patients needing alternative hemodialysis access in decades. The company pitches it as a ready-to-use biologic conduit that has performed predictably in patients with small vessel anatomy, diabetes or obesity, factors that complicate AV fistula maturation. Nearly 500,000 Americans currently depend on hemodialysis for survival, according to the company.
TopicsHumacyte · HUMA · FDA · ATEV · Symvess · Laura Niklason · end-stage kidney disease · hemodialysis
Source: finance.yahoo.com
Written by AI from verified reporting.
More stories
- Health & science technologyreview.com 0 viewsDonated liver survives seven weeks outside the body in Sydney record
- Health & science finance.yahoo.com 0 viewsSanofi's next-gen rabies shot VaxRabeo scores EU approval
- Health & science reuters.com Caught by @mimi💕💕 1 viewAbbVie Bets Up to $2.54B on Disco's Next-Gen Cancer Drugs
- Health & science fnob.it 1 viewTenK10K maps 5 million immune cells, linking DNA variants to 16 diseases

